Calidi Biotherapeutics, Inc. CLDI 深 沪
等待开盘 04-21 09:30:00 美东时间
0.2499
-0.025
-9.13%
华盛通- 最 高0.266
- 今 开0.266
- 成交量 128.72万股
- 最 低 0.24
- 昨 收 0.275
- 总市值 272.28万
- 52周最高 19.20
- 市盈率 静 --
- 换手率 11.81%
- 52周最低 0.2088
- 委 比 0.00%
- 总股本 1089.57万
- 历史最高 2886.00
- 量 比 0.78
- 振 幅 9.45%
- 历史最低 0.2088
- 每 手 1
- 风险率 2.29%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Calidi Showcases RedTail Platform Data Highlighting Dual T-Cell Activation Strategy For Solid Tumors At AACR 2026
Calidi Biotherapeutics, Inc. (NYSE:CLDI) ("Calidi" or the "Company"), a biotechnology company pioneering the development of targeted genetic medicines, presented new data at the American Association of Cancer Research (AACR) annual meeting in San Diego, California on April 19, 2026.
04-20 20:06
Calidi Biotherapeutics To Present New Data On Its Approach Of Simultaneously Activating T-Cells At American Association Of Cancer Research Annual Meeting
Calidi Biotherapeutics, Inc. (NYSE American: CLDI) ("Calidi" or the "Company"), a biotechnology company pioneering the development of targeted genetic medicines, will present new data at the American Association of
04-01 20:03
Calidi Biotherapeutics Partners With Avance Clinical On Initiating First-In-Human Clinical Trial For CLD-401 In Australia
Calidi Biotherapeutics, Inc. (NYSE:CLDI) ("Calidi" or the "Company"), a biotechnology company pioneering the development of targeted genetic medicines, today announced a partnership with Avance Clinical, a full-service
03-24 20:03
Calidi Biotherapeutics Presents Manufacturing Process For CLD-401
Calidi Biotherapeutics, Inc. (NYSE American: CLDI) ("Calidi" or the "Company"), a biotechnology company pioneering the development of targeted genetic medicines, today presented on its proprietary manufacturing process
03-12 20:07
Calidi Biotherapeutics shares are trading lower after the company announced the pricing of its $5.2 million offering of 10.5 million shares.
Calidi Biotherapeutics shares are trading lower after the company announced the...
03-06 22:25
Calidi Biotherapeutics Announces Pricing On $5.2M Offering Of 10.5M Shares
10,519,631 units, with each unit consisting of one share of common stock (or pre-funded warrant in lieu thereof), (ii) one 6 month warrant to purchase one share of common stock, (iii) one 12 month warrant to purchase one
03-06 21:35
Calidi Biotherapeutics (CLDI) Stock Plunges 35% After Hours — Here's Why
Calidi Biotherapeutics shares plunged after hours following a public offering announcement, trading near their 52-week low.
03-06 15:15
Calidi Biotherapeutics Reveals Proposed Public Offering; No Size Disclosed
Calidi Biotherapeutics, Inc. (NYSE:CLDI) ("Calidi" or the "Company"), a biotechnology company pioneering the development of targeted genetic medicines, today announced that it intends to offer and sell, subject to market
03-06 06:59
Calidi Biotherapeutics Presents Data On Approach To Use Of BiTEs In Solid Tumors By Utilizing RedTail Platform At AACR-IO Conference
Calidi Biotherapeutics, Inc. (NYSE:CLDI) ("Calidi" or the "Company"), a biotechnology company pioneering the development of targeted genetic medicines, today presented data on its novel approach to the use of BiTEs in
02-20 21:05
Calidi Biotherapeutics Q3 EPS $(2.21) Misses $(1.68) Estimate
Calidi Biotherapeutics (AMEX:CLDI) reported quarterly losses of $(2.21) per share which missed the analyst consensus estimate of $(1.68) by 31.55 percent. This is a 71.67 percent increase over losses of $(7.80) per share
2025-11-14 05:22
